General Information of Drug (ID: DMMLQZJ)

Drug Name
Indan-1-ol Drug Info
Synonyms
Indan-1-ol; 1-Indanol; Indanol; L-INDANOL; SCHEMBL1747186; YIAPLDFPUUJILH-UHFFFAOYSA-N; (-)-indanol; 1-Hydroxyhydrindene; 1-Hydroxyindan; 1-Hydroxyindane; 1-INDANOL; 1-Indanol, 98%; 1-Indanole; 1H-Inden-1-ol, 2,3-dihydro-; 1H-Inden-1-ol,3-dihydro-; 1H-Indenol, 2,3-dihydro-; 1H-Indenol,2,3-dihydro-; 2,3-Dihydro-1H-inden-1-ol; 36643-74-0; 4-06-00-03824 (Beilstein Handbook Reference); AC1L2L5X; AC1Q7AG7; ACMC-1ATT8; ACMC-20aphe; BRN 2042960; CHEBI:16697; CTK4H6942; EINECS 253-146-4; KS-00000MBA; MFCD00003797; NSC31258; SCHEMBL57132
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
22819
ChEBI ID
CHEBI:16697
CAS Number
CAS 6351-10-6
TTD Drug ID
DMMLQZJ
INTEDE Drug ID
DR2001

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Metabolized By Aldo-keto reductase 1C3 (AKR1C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Solid tumour/cancer 2A00-2F9Z Approved [3]
Fenofibric acid DMGO2MC Cardiovascular disease BA00-BE2Z Approved [4]
Androsterone DMITJAK N. A. N. A. Phase 3 [2]
Trastuzumab Emtansine DMU1LXS HER2-positive breast cancer 2C60-2C65 Phase 2 [5]
4-oxo-nonenal DMPX1J9 Discovery agent N.A. Investigative [6]
Acenaphthenol DMT3QYZ Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Aldo-keto reductase 1C3 (AKR1C3) Main DME DEGQTXO AK1C3_HUMAN Substrate [2]

References

1 A Publication of Reliable Methods for the Preparation of Organic Compounds: alpha-HYDRINDONE
2 Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry. 1998 May 12;37(19):6781-90.
3 Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6.
4 In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
5 The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
6 Instability of C154Y variant of aldo-keto reductase 1C3. Chem Biol Interact. 2017 Oct 1;276:194-202.